4.6 Review

Optimising monitoring in the management of Crohn's disease: A physician's perspective

期刊

JOURNAL OF CROHNS & COLITIS
卷 7, 期 8, 页码 653-669

出版社

OXFORD UNIV PRESS
DOI: 10.1016/j.crohns.2013.02.005

关键词

Diagnosis; Monitoring; Imaging; Biomarkers; Endoscopy; Disease activity index

资金

  1. Abbott Laboratories
  2. Merck Sharp and Dohme Corp.
  3. UCB Pharma
  4. Janssen
  5. Takeda
  6. ActoGeniX
  7. Albireo Pharma
  8. Amgen
  9. AstraZeneca
  10. Bayer AG
  11. Biogen Idec
  12. Boehringer Ingelheim GmbH
  13. Bristol-Myers Squibb
  14. Cellerix
  15. Centocor
  16. ChennoCentryx
  17. Cosmo Technologies
  18. Danone Research
  19. Elan Pharmaceuticals
  20. Genetech
  21. Giuliani SpA
  22. Given Imaging
  23. GlaxoSmithKline
  24. Hutchison MediPharma
  25. Merck Sharp and Dohme Corp
  26. Neovacs
  27. Ocera Therapeutics Inc.
  28. Otsuka America Pharmaceutical
  29. Pfizer
  30. Shire Pharmaceuticals
  31. Prometheus Laboratories
  32. Sanofi-Aventis
  33. Schering-Plough
  34. Synta Pharmaceuticals Corp
  35. Teva
  36. Therakos
  37. Tillotts Pharma
  38. Wyeth
  39. Vifor Pharma
  40. Alba Therapeutics
  41. Atherys
  42. Axcan
  43. Celgene
  44. Elan /Biogen
  45. Genentech
  46. Given Imaging Inc.
  47. ISIS
  48. Janssen-Ortho
  49. Merck
  50. Ore Pharm
  51. Pfizer, Inc.
  52. Procter and Gamble
  53. Prometheus Therapeutics and Diagnostics
  54. Protein Design Labs
  55. Salix Pharmaceuticals
  56. Santarus
  57. Zeland Pharma
  58. Novo Nordisk
  59. Novartis
  60. MSD
  61. Ferring
  62. Schering Plough
  63. Essex
  64. UCB
  65. Falk
  66. Tygenics

向作者/读者索取更多资源

Management of Crohn's disease has traditionally placed high value on subjective symptom assessment; however, it is increasingly appreciated that patient symptoms and objective parameters of inflammation can be disconnected. Therefore, strategies that objectively monitor inflammatory activity should be utilised throughout the disease course to optimise patient management. Initially, a thorough assessment of the severity, location and extent of disease is needed to ensure a correct diagnosis, identify any complications, help assess prognosis and select appropriate therapy. During follow-up, clinical decision-making should be driven by disease activity monitoring, with the aim of optimising treatment for tight disease control. However, few data exist to guide the choice of monitoring tools and the frequency of their use. Furthermore, adaption of monitoring strategies for symptomatic, asymptomatic and post-operative patients has not been well defined. The Annual excHangE on the ADvances in Inflammatory Bowel Disease (IBD Ahead) 2011 educational programme, which included approximately 600 gastroenterologists from 36 countries, has developed practice recommendations for the optimal monitoring of Crohn's disease based on evidence and/or expert opinion. These recommendations address the need to incorporate different modalities of disease assessment (symptom and endoscopic assessment, measurement of biomarkers of inflammatory activity and cross-sectional imaging) into robust monitoring. Furthermore, the importance of measuring and recording parameters in a standardised fashion to enable longitudinal evaluation of disease activity is highlighted. (C) 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据